NYSE:RVTYLife Sciences
Revvity (RVTY) Valuation Check As Q1 Beat, Guidance Shift And China Divestiture Plan Draw Investor Focus
Revvity (RVTY) is drawing fresh attention after reporting first quarter 2026 results that exceeded analyst expectations on revenue and adjusted EPS, while also lowering full year guidance and moving to divest its China Immunodiagnostics business.
See our latest analysis for Revvity.
Despite the Q1 beat and corporate moves around guidance, governance and dividends, recent share price performance has been weak, with a 90 day share price return of 14.46% and a 1 year total shareholder return...